Robeco Institutional Asset Management B.V. decreased its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 7.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,706 shares of the company's stock after selling 4,421 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in Cencora were worth $14,935,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in COR. Hoey Investments Inc. acquired a new stake in Cencora during the 1st quarter worth approximately $28,000. Banque Transatlantique SA purchased a new stake in shares of Cencora during the fourth quarter worth $29,000. SBI Securities Co. Ltd. purchased a new stake in shares of Cencora during the fourth quarter worth $30,000. Vermillion Wealth Management Inc. acquired a new stake in shares of Cencora in the fourth quarter valued at $38,000. Finally, OFI Invest Asset Management purchased a new position in Cencora in the fourth quarter valued at $41,000. Hedge funds and other institutional investors own 97.52% of the company's stock.
Insider Transactions at Cencora
In other news, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the transaction, the chairman now directly owns 311,913 shares in the company, valued at approximately $91,271,982.06. This trade represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer now directly owns 47,582 shares in the company, valued at $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,127 shares of company stock worth $9,812,296. Corporate insiders own 10.80% of the company's stock.
Cencora Stock Performance
Shares of COR opened at $299.71 on Friday. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. Cencora, Inc. has a 52-week low of $218.65 and a 52-week high of $309.35. The stock has a 50 day moving average price of $289.95 and a 200 day moving average price of $265.22. The company has a market capitalization of $58.09 billion, a price-to-earnings ratio of 34.77, a price-to-earnings-growth ratio of 1.48 and a beta of 0.58.
Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The business had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter in the prior year, the business posted $3.80 EPS. The company's revenue for the quarter was up 10.3% on a year-over-year basis. Research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.
Cencora Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.73%. The ex-dividend date was Friday, May 16th. Cencora's payout ratio is 25.52%.
Analyst Ratings Changes
Several brokerages have weighed in on COR. Wall Street Zen upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Wells Fargo & Company upgraded shares of Cencora from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Citigroup raised their target price on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a report on Thursday, May 8th. UBS Group lifted their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Finally, Robert W. Baird increased their price objective on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $306.91.
Check Out Our Latest Report on Cencora
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
See Also
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
